Prevalence of polycystic ovary syndrome in reproductive-aged women
Abstract
Polycystic ovary syndrome (PCOS) is one of the most communal endocrine illnesses in women of reproductive age. The clinical and biochemical presentation is heterogeneous, but elevated serum concentrations of androgens are the most consistent biochemical abnormality and may be considered to be the hallmark of the syndrome. Many women with PCOS also have insulin resistance and hyperinsulinemia, which may contribute to the clinical and endocrine abnormality. Obesity, central obesity and insulin resistance are powerfully concerned in its etiology. Dietary weight loss is recommended as the primary treatment approach. Our aim is to control prevalence, etiology of PCOS, diagnosis and its association numerous factors in PCOS patients, so as to encourage young women to treat timely treatment and prevent long term complications.
Downloads
References
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology & Metabolism. 1998 Sep 1;83(9):3078-82.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology & Metabolism. 2004 Jun 1;89(6):2745-9.
Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinology andmetabolism clinics of North America. 1999 Jun 1;28(2):247-63.
Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001 Mar 13;103(10):1410-5.
Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology. 2004 Oct 1;18(5):671-83.
Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with the polycystic ovarian syndrome. Human reproduction. 2001 Feb 1;16(2):226-9.
Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Human Reproduction. 2003 Jul 1;18(7):1438-41.
Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. The Journal of Clinical Endocrinology & Metabolism. 1986 May 1;62(5):904-10.
Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. The Journal of Clinical Endocrinology & Metabolism. 1988 Sep 1;67(3):460-4.
Acién P, Quereda F, Matallı́n P, Villarroya E, López-Fernández JA, Acién M, Mauri M, Alfayate R. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertility and sterility. 1999 Jul 1;72(1):32-40.
Dale PO, Tanbo T, Vaaler S, Åbyholm T. Bodyweight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertility and sterility. 1992 Sep 1;58(3):487-91.
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and sterility. 2005 May 1;83(5):1454-60.
Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello MF. Guideline Development Groups. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Medical Journalof Australia. 2011; 195:S65-112.
Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, Tfayli H. The diagnosis of polycystic ovary syndrome during adolescence. Hormone research in paediatrics. 2015; 83(6):376-89.
Kamangar F, Okhovat JP, Schmidt T, Beshay A, Pasch L, Cedars MI, Huddleston H, Shinkai K. Polycystic ovary syndrome: special diagnostic and therapeutic considerations for children. Pediatric dermatology. 2015 Sep;32(5):571-8.
Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertility and sterility. 2001 Jan 1;75(1):53-8.
Moll Jr GW, Rosenfield RL. Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. The Journal of pediatrics. 1983 Mar ;102(3):461-4.
Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Insulin, androgen, and gonadotropin concentrations, body mass index, and waist to hip ratio in the first years after menarche in girls with regular menstrual cycles, irregular menstrual cycles, or oligomenorrhea. The Journal of Clinical Endocrinology & Metabolism. 2000 Apr 1;85(4):1394-400.
Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. The Journal of Clinical Endocrinology & Metabolism. 2009 May 1;94(5):1579-86.
Rosenfield RL. Adolescent anovulation: maturational mechanisms and implications. The Journal of Clinical Endocrinology & Metabolism. 2013 Sep; 98(9):3572-83.
Powers SE, Uliassi NW, Sullivan SD, Tuchman LK, Mehra R, Gomez-Lobo V. Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome. Journal of pediatric and adolescent gynecology. 2015 Feb 1;28(1):43-6.
Tfayli H, Arslanian S. Menstrual health and the metabolic syndrome in adolescents. Annals of the New York Academy of Sciences. 2008;1135:85.
Franks S. Adult polycystic ovary syndrome begins in childhood. Best Practice & Research Clinical Endocrinology & Metabolism. 2002 Jun 1;16(2):263-72.
WIKSTEN‐ALMSTRÖMER MA, Hirschberg AL, Hagenfeldt K. Prospective follow‐up of menstrual disorders in adolescence and prognostic factors. Acta obstetricia et gynecologica Scandinavica. 2008 Nov;87(11):1162-8.
Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocrine reviews. 2010 Oct 1;31(5):702-55.
Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. Best Practice & Research Clinical Endocrinology & Metabolism. 2011 Dec 1;25(6):861-73.
.Hansen KA, Tho SP, Hanly M, Moretuzzo RW, McDonough PG. Massive ovarian enlargement in primary hypothyroidism. Fertility and sterility. 1997 Jan;67(1):169- 71.
Hochereau-de Reviers MT, Copin M, Seck M, Monet-Kuntz C, Cornu C, Fontaine I, Perreau C, Elsen JM. Stimulation of testosterone production by PMSG injection in the ovine male: effect of breed and age and application to males carrying or not carrying the “F” Booroola gene. Animal Reproduction Science. 1990 Aug 1;23(1):21-32.
Fraczek M, Szumala-Kakol A, Dworacki G, Sanocka D, Kurpisz M. In vitro reconstruction of inflammatory reaction in human semen: effect on sperm DNA fragmentation. Journal of reproductive immunology. 2013 Nov 1;100(1):76-85.
Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine. 2005 Mar 24;352(12):1223-36.
Horejsi R, Möller R, Rackl S, Giuliani A, Freytag U, Crailsheim K, Sudi K, Tafeit E. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. American Journal of Physical Anthropology: The Official Publication of the American Association of Physical Anthropologists. 2004 Jul;124(3):275-81.
Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reproduction. 2001 Jun 1;16(6):1255-60.
Ek I, Arner P, Rydén M, Holm C, Thörne A, Hoffstedt J, Wahrenberg H. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes. 2002 Feb 1;51(2):484-92.
Swaroop A, Jaipuriar AS, Kumar P, Bagchi D. Efficacy of a novel fenugreek seed extract (Furocyst) in polycystic ovary syndrome (PCOS). Planta Medica. 2016 Dec;82(S 01): P1097.
Apter D. Endocrine and metabolic abnormalities in adolescents with a PCOSlike condition: consequences for adult reproduction. Trends in Endocrinology & Metabolism. 1998 Feb 1;9(2):58-61.
Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo‐amenorrhoea at age 18 years. Human Reproduction. 2004 Feb 1;19(2):383-92.
Venturoli S, Porcu E, Fabbri R, Pluchinotta V, Ruggeri S, Macrelli S, Paradisi R, Flamigni C. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatric research. 1995 Dec;38(6):974-80.
Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. seminars in reproductive medicine 2008 Jan (Vol. 26, No. 01, pp. 111-120). © Thieme Medical Publishers.
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The journal of clinical endocrinology & metabolism. 1999 Jan 1;84(1):165-9.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. 2002 Feb;346(6):393-403.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic syndrome: towards a rational approach. Dunaif A, Givens JR, HaseltineFP, and others, Eds. Polycystic ovary syndrome. Boston: Blackwell Scientific. 1992:337-84.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-MorrealeHF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and sterility. 2009 Feb 1;91(2):456-88.
Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. The Journal of Clinical Endocrinology & Metabolism. 2006 Mar 1;91(3):786-9.
Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive biomedicine online. 2009 Jan 1;19(3):398- 405.
Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, EscobarMorreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human reproduction update. 2014 May 1;20(3):334-52.
Holte J, Bergh T, Berne CH, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 1995 Sep 1;80(9):2586-93.
Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003 Feb 1;88(2):812-9.
Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. MetabolismClinical and Experimental. 1995 May1;44(5):611-6.
Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. The Journal of Clinical Endocrinology & Metabolism. 1999 Apr 1;84(4):1470-4.
Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietarymacronutrient restriction enhance eight loss in polycystic ovary syndrome. The American journal of clinical nutrition. 2006 Jun 1;84(1):77-87.
Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Human reproduction. 1995 Oct 1;10(10):2705-12.
Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results inimprovement in reproductive outcome for all forms of fertility treatment. Human Reproduction (Oxford, England). 1998 Jun 1;13(6):1502-5.
Kiddy DS, Hamilton‐Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical endocrinology. 1992 Jan;36(1):105-11.
Jakicic JM, Otto AD. Treatment and prevention of obesity: what is the role of exercise?. Nutrition reviews. 2006 Feb1;64(suppl_1):S57-61.
Lynch J, Helmrich SP, Lakka TA, Kaplan GA, Cohen RD, Salonen R, Salonen JT. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Archives of internal medicine. 1996 Jun 24;156(12):1307-14.
Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. New England Journal of Medicine. 2002 Sep5;347(10):716-25.
Lee IM, Hsieh CC, Paffenbarger RS. Exercise intensity and longevity in men: the Harvard Alumni Health Study. Jama. 1995 Apr 19;273(15):1179-84.
DiLorenzo TM, Bargman EP, Stucky-Ropp R, Brassington GS, Frensch PA, LaFontaine T. Long-term effects of aerobic exercise on psychological outcomes. Preventive medicine. 1999 Jan 1;28(1):75- 85.
Scully D, Kremer J, Meade MM, Graham R, Dudgeon K. Physical exercise and psychological well being: a critical review. British journal of sports medicine. 1998 Jun 1;32(2):111-20.
Penedo FJ, Dahn JR. Exercise and wellbeing: a review of mental and physical health benefits associated with physicalactivity. Current opinion in psychiatry. 2005 Mar 1;18(2):189-93.
Tang T, Norman RJ, Balen AH, Lord JM. Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2003(2).
Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’KeefeM, Ghazzi MN, PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism. 2001 Apr 1;86(4):1626-32.
